Your privacy choices

Sentimentor uses optional analytics cookies to understand visits and improve the product. Essential cookies remain enabled either way.

Privacy policy
← Back to the evidence summary

NVDA · Q2 FY2027 · evidence through August 26, 2026

Follow the evidence behind the claims.

See which documents support each finding, the exact rows and periods used, and the calculation connecting those inputs to the conclusion.

Source-backed worked example · not a recorded Augur run. The tables document source checks, not an independent audit of the issuer’s accounting.

Published · Updated · Editorial review by Sentimentor Research

Editorial standardsResearch methodologyData sources and limitations

Does the growth story hold up?

  • Chart

    What happened?

    Price, volume and technical context.

  • News

    Why?

    Events, headlines and market reaction.

  • Filings

    What changed?

    What the company actually disclosed.

  • Sentiment

    How is the market reacting?

    Signals around the underlying story.

  • Counterevidence

    What contradicts the thesis?

    The context you might miss when confirming your idea.

  • Notes

    What do I believe now?

    Your conclusion after reviewing the sources.

The research method available in Sentimentor

  1. 1. Locate primary documents

    Augur’s filing lookup identifies the issuer, reporting period and official document URL.

    get_company_filings
  2. 2. Read beyond the headline

    Read the source tables and footnotes; distinguish quarterly from cumulative cash flows.

    fetch_url
  3. 3. Reconcile before concluding

    Use period-tagged SEC facts and show arithmetic, then keep reported facts separate from interpretation.

    get_sec_financial_facts

Tool names describe the available research workflow; the evidence tables below document this worked example.

Claim check 01

Check growth against the same quarter

Read the GAAP revenue row, then cross-check the 10-Q. Match issuer, business scope, fiscal period and units—not just a similar-looking number.

Check growth against the same quarter: extracted source rows
Source rowFiscal periodValueDocument & locator
Company revenueQ2 FY2027 · three months ended July 26, 2026$96.221BNVIDIA Q2 FY2027 earnings release

GAAP summary → Revenue → Q2 FY27

Prior-year company revenueQ2 FY2026 · three months ended July 27, 2025$46.743BNVIDIA Q2 FY2027 Form 10-Q

Part I, Item 1 → income statement → Revenue → three-month comparative column

Reproduce the calculation

($96.221B ÷ $46.743B − 1) × 100 = 105.9%

Supported: quarterly revenue more than doubled. The release rounds the growth rate to 106%.

This supports reported sales growth, not an explanation of the share price or a valuation conclusion.

Claim check 02

Dig below earnings: reconstruct quarterly cash flow

The Q2 10-Q cash-flow statement covers six months. Subtract Q1 to isolate Q2, then check that result against the release before comparing it with quarterly net income.

Dig below earnings: reconstruct quarterly cash flow: extracted source rows
Source rowFiscal periodValueDocument & locator
Operating cash flowH1 FY2027 · six months ended July 26, 2026$74.421BNVIDIA Q2 FY2027 Form 10-Q

Part I, Item 1 → cash flows → operating-activities subtotal

Operating cash flowQ1 FY2027 · three months ended April 26, 2026$50.344BNVIDIA Q1 FY2027 Form 10-Q

Part I, Item 1 → cash flows → operating-activities subtotal

Reported operating cash flowQ2 FY2027 · three months ended July 26, 2026$24.077BNVIDIA Q2 FY2027 earnings release

Cash-flow statement → operating-activities subtotal → three-month column

GAAP net incomeQ2 FY2027 · three months ended July 26, 2026$59.688BNVIDIA Q2 FY2027 Form 10-Q

Part I, Item 1 → income statement → Net income → three-month column

Reproduce the calculation

$74.421B − $50.344B = $24.077B Q2 operating cash flow

$24.077B ÷ $59.688B × 100 = 40.3%

What the cash-flow detail adds

Q2 operating cash-flow adjustments include receivables −$22.346B, inventory −$5.784B, and the equity-gain reversal −$7.771B. These are selected reconciliation items—not the entire bridge or identical changes in balance-sheet balances.

Supported: quarterly operating cash flow was below quarterly net income. Both measures cover the same three months.

This analytical ratio is not a GAAP margin. One quarter cannot establish a persistent collection problem.

Claim check 03

Separate the forecast from the result

Use the Outlook section, not a historical-results column. Retain its future period and tolerance instead of presenting the midpoint as achieved revenue.

Separate the forecast from the result: extracted source rows
Source rowFiscal periodValueDocument & locator
Revenue guidanceQ3 FY2027 · forecast issued August 26, 2026$108.0B ±2%NVIDIA Q2 FY2027 earnings release

Outlook → third-quarter revenue

GAAP gross-margin guidanceQ3 FY2027 · forecast issued August 26, 202674.0% ±0.5 percentage pointsNVIDIA Q2 FY2027 earnings release

Outlook → third-quarter GAAP gross margin

Reproduce the calculation

$108.0B × (1 ±2%) = $105.84B–$110.16B

Supported as management guidance—not a completed result.

A subsequent earnings release is needed to test delivery; this outlook does not prove future returns.

Reproduce the homepage chart
PeriodRevenue ($B)GAAP gross marginSource
Q3 FY2657.00673.4%GAAP summary
Q4 FY2668.12775.0%GAAP summary
Q1 FY2781.61574.9%GAAP summary
Q2 FY2796.22175.0%GAAP summary

Revenue: source USD millions divided by 1,000. Gross margins: issuer-reported GAAP percentages. All four columns are standalone quarters, not annual or year-to-date totals.

Source record

What the checks support—and what they don’t

Sales growth supports business expansion. Lower quarterly cash conversion warrants following collections and working capital; it does not, by itself, establish bad debt or weak demand.

This example tests company disclosures, not the share price. Future collections, valuation and subsequent results remain outside its evidence cutoff. No trade recommendation or future return is established.

What this changes in a decision

A headline gives you a reason to look. Evidence gives you conditions to act.

NVDA · Worked example using evidence through August 26, 2026. Choose the decision you are weighing.

The starting assumption

Revenue doubled. Is that enough reason to buy?

Considering buying

Sentimentor’s analysis

Augur separates a growing business from a justified entry.

Revenue grew 106% year over year, while quarterly operating cash flow was 40.3% of net income.

The reported revenue growth supports the business expansion story. It does not tell you whether that growth is already reflected in the share price.

Check the reported figures

The decision it supports

Make the entry conditional.

The growth figure earns a closer look. It does not establish an attractive entry price. Compare valuation and current price with your thesis, then decide whether the potential upside justifies the downside.

Read Augur’s reasoning · Considering buying
  • Operating cash flow trails reported profit. Augur’s supplied analysis identifies working-capital cash movements and noncash investment gains as reasons to examine the gap, rather than treating earnings as cash available to the business.
  • This investigation does not establish an entry price or future cash conversion. Those checks remain open before a trade can be justified.
Inspect the filing and cash-flow explanation

Scenario-specific interpretation of the supplied Augur research, not a separate recorded recommendation.

How the decision changes

Illustrative comparison: the “without” path assumes the investor acts on the headline or ratio alone.

Without Augur

Buy on the growth headline.

An investor focused only on doubled revenue could enter immediately, assuming strong growth also means strong cash generation and an attractive price.

With Augur

Keep NVDA on the shortlist; wait for the entry checks to pass.

The decision moves from “growth means buy” to “growth earns a closer look; price, cash generation and downside must justify an entry.”

What to do next: Before an entry: define the price you would pay, the loss you can tolerate, and the evidence that would invalidate the thesis. If those checks do not pass, wait or choose another candidate.

Sentimentor repeats the process across new candidates and existing positions: narrow the shortlist, challenge the reason to trade, test your rules, and revisit the decision when the evidence changes.

Illustrative decision framework, not a documented customer trade or a measured return. This evidence alone cannot establish a buy/sell signal or prove that a decision made money.

Investigate your own stock

Personal Augur research uses your trial or plan allowance. Review the draft before sending.